Company Filing History:
Years Active: 2022-2025
Title: Lorenzo De Lichtervelde: Innovator in Alpha-Synuclein Research
Introduction
Lorenzo De Lichtervelde is a prominent inventor based in Brussels, Belgium. He has made significant contributions to the field of biomedical research, particularly in the development of treatments for neurodegenerative diseases. With a total of 3 patents to his name, his work focuses on innovative solutions for complex health issues.
Latest Patents
Lorenzo's latest patents include groundbreaking research on anti-alpha-synuclein antibodies. These inventions relate to antibodies and fragments capable of binding to alpha-synuclein in both monomeric and fibrillar forms. The primary goal of these antibodies is to prevent the aggregation of alpha-synuclein, which is a key factor in the development of alpha-synucleinopathies, including Parkinson's disease. This research holds promise for advancing treatment options for patients suffering from these debilitating conditions.
Career Highlights
Lorenzo De Lichtervelde is associated with UCB Biopharma Srl, where he continues to push the boundaries of scientific research. His work has been instrumental in developing therapies that target critical pathways involved in neurodegeneration. His innovative approach and dedication to research have established him as a key figure in his field.
Collaborations
Lorenzo collaborates with notable professionals in the industry, including Patrick Downey and Terence Seward Baker. These partnerships enhance the scope and impact of his research, fostering an environment of innovation and discovery.
Conclusion
Lorenzo De Lichtervelde's contributions to the field of alpha-synuclein research are invaluable. His innovative patents and collaborations position him as a leading inventor in the quest for effective treatments for neurodegenerative diseases.